XTL Biopharmaceuticals discloses Nasdaq listing deficiency notice

XTL Biopharmaceuticals “announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on the Nasdaq. The Notification Letter does not impact the Company’s listing on the Nasdaq Capital Market at this time and the Company’s ADSs continue to trade on the Nasdaq Capital Market under the symbol “XTLB“. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 15, 2024, to regain compliance. The Notice states that to regain compliance, the bid price for the ADSs must close at $1.00 per ADS or more for a minimum of ten (10) consecutive business days during the compliance period ending April 15, 2024.”